HOLD - existing holders should stay with tighter risk controls, reduced position sizing on adds, hedging, and conservative trailing stops

• Record revenue, 91.5% ROE, 8.65B trailing FCF covering 5.4B dividend, forward P/E of 15.4 support hold decision
• 0.43 beta argument is empirically falsified - stock fell 15.4% in two weeks despite low beta
• MACD histogram at negative 9.03 and still expanding indicates accelerating downside, not a coiled spring
• 10 EMA collapsed from 436 to 398 in seven sessions; 50 SMA near loss of support; price at lower Bollinger band 369
• RSI cycle from 79 to 32 is not automatically bullish without price confirmation
• Pelacarsen overhang is multi-month, not one-week event - institutional capital rotating out until differentiation
• IMDELLTRA opportunity requires FDA approval (quarters) and will be overwhelmed by current macro headwinds
• Macro regime extreme: 10-year at highest since 2007 briefly above 5%, oil above 100 (referenced as high as 105), Polymarket pricing zero Fed cuts 2026 at 94%, US recession odds up 12.5pp to 20%
• Balance sheet vulnerability: net debt of 43.3B, debt-to-equity of 4.9, negative tangible book value, 670M quarterly interest expense
• ATR elevated at 10.87 warrants position sizing at no more than 1/3 typical notional on future adds
• Protective puts recommended at strikes 350-360 for 60-90 days to hedge against 200 SMA break and test of June 336 swing low
• 2 ATR trailing stop suggested (around 354-355) tightening once above 398
• 398 reclaim requires confirmed close with volume and macro stabilization (10-year below 4.7 or oil below 100) before fresh capital commitment
• Q3 earnings in October, olpasiran data updates, and Fed/Treasury policy shifts are explicit catalyst-driven re-evaluation triggers

→ vs aggressive: Beta 0.43 argument empirically falsified - low beta stock fell 15.4% in two weeks during idiosyncratic shock with hostile macro overlay

→ vs aggressive: MACD histogram at negative 9.03 and expanding signals accelerating downside, not exhaustion - extreme readings can signal trend just starting, not ending

→ vs aggressive: RSI completing cycle from 79 to 32 is context not signal - RSI can sit at 30 for weeks in sustained downtrend

→ vs aggressive: Mechanism differentiation (siRNA vs antisense) does not matter for stock price action - market de-rates entire Lp(a) class on Phase 3 failure

→ vs aggressive: IMDELLTRA requires quarters for FDA approval and commercial uptake; biotech de-rated in higher-for-longer rate regime

→ vs aggressive: Macro analysis has significant gap - 10-year above 5%, oil at 105, zero Fed cuts priced for 2026, recession odds at 20% creates regime where multiple compression hits biotech hardest

→ vs aggressive: Balance sheet glossed over entirely - 43.3B net debt, 4.9 debt-to-equity, negative tangible book value, 670M quarterly interest expense creates real vulnerability in recession scenario

HOLD with refined structure: half-notional sizing, stop at $356 on confirmed close basis, no protective puts needed, entry at $398 only on confirmed close with above-average volume and MACD histogram stop-expanding; remove macro stabilization gate; monitor Q3 earnings, olpasiran updates, and 10-year moves past 5.25% as catalyst triggers.

• AMGN fundamentals intact: Q2 revenue $10.05B, EPS $4.37, ROE 91.5%, forward P/E 15.4 with double-digit earnings growth
• Olpasiran and pelacarsen are mechanistically different; sell-side acknowledges this; market is wrong to assume failure by association
• Company generates $8.5B in trailing free cash flow; fortress-building on downside ignores the actual financial profile
• Aggressive analyst wrong on 0.43 beta: 15.4% loss in 8 sessions directly contradicts defensive framing
• Aggressive analyst wrong on coiled spring: MACD histogram at negative 9.03 and still expanding is falling knife, not oversold bounce setup
• Conservative analyst correct on pelacarsen overhang as multi-week, not one-week, story
• Conservative analyst correct on biotech multiple compression in higher-for-longer regime
• Conservative analyst correct on real balance sheet leverage: $670M quarterly interest expense, 10-year above 5%
• Conservative analyst's hedging framework internally inconsistent: argues unlimited downside but recommends hold with expensive protective puts at $350-$360 strikes
• Conservative analyst's macro gate too restrictive: waiting for 10-year below 4.7% or oil below $100 means chasing 20-30% higher
• Conservative analyst's stop at $354 (2 ATR) too tight relative to 200 SMA at $355.79; creates wick-driven false breakout risk
• Market partially right and partially wrong simultaneously: right on pelacarsen class-effect concerns, wrong to apply pre-revenue biotech compression to $38B TTM revenue company with 91.5% ROE
• Entry at $398: require confirmed close above with above-average volume AND MACD histogram stop-expanding; two conditions, not five
• Base case is mean reversion to $398 then $421, not full re-rating to all-time highs; works in any macro short of outright credit event
• Protective puts at $350-$360 overlap with $356 stop; double-cost inefficiency makes them unnecessary when stop already defines the tail
• Half-notional sizing respects $10.87 ATR volatility without underweighting the opportunity; one-third notional excessive for this cash flow profile
• MACD histogram contraction is single most important momentum confirmation; RSI hook above 40 is nice-to-have, not required

→ vs aggressive: Keeps invoking 0.43 beta as if it's descriptive when empirical evidence directly contradicts it: 15.4% loss in 8 sessions during flight to quality. Can't have low beta as both bullish justification and reason to ignore actual price action.

→ vs aggressive: Coiled spring framing is wrong: MACD histogram at negative 9.03 and still expanding is falling knife with momentum, not coiled spring. Oscillators stay oversold for weeks in sustained downtrends; lower Bollinger can stay broken.

→ vs aggressive: Binary framing of market-right versus market-wrong misses that market is partially right and partially wrong simultaneously; honest read acknowledges both the legitimate class-effect questions and the real mechanistic differentiation.

→ vs conservative: Hedging framework internally inconsistent: constructs case for unlimited downside then recommends hold with protective puts. If genuinely as severe as described, should trim, not hold with expensive overlapping protection at $350-$360 (right at $356 stop level, creating double-cost).

→ vs conservative: Macro stabilization gate too restrictive: waiting for 10-year below 4.7% or oil below $100 means chasing 20-30% higher. High-quality compounder thesis means buying through macro cycles, not after them.

→ vs conservative: Stop structure at $354 (2 ATR) too tight, sitting right at 200 SMA $355.79; gives no room for bounce at that level and creates false breakout risk on any wick-driven touch. Original $356 stop more reasonable but requires confirmed close with follow-through, not just touch.